CushieBlog

Cushing’s Help RSS Feed

• 📰 Withdrawal Study Details Effects of Levoketoconazole in Cushing's Syndrome
  Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.
• 📰 Osilodrostat Improves Physical Manifestations of Hypercortisolism for Most Adults
  Osilodrostat is associated with improvements in physical manifestations of hypercortisolism and reductions in mean body weight and BMI in adults with Cushing’s syndrome, according to a speaker.
• 📰Crinetics Pharmaceuticals (CRNX) Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study
  ACTH is the key regulator of the hypothalamic-pituitary adrenal (HPA) axis controlling adrenal activation. It is regulated by cortisol via a negative feedback loop that acts to inhibit ACTH secretion. This feedback loop is dysregulated in diseases of excess ACTH. In Cushing’s disease, a benign pituitary tumor drives excess ACTH secretion even in the presence […]
• 📰Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology
  Clinical trial analyses focus on the human body’s homeostatic response to potent HSD-1 inhibition by SPI-62. Results highlight that urinary free cortisol is distinct from intracellular cortisol that causes symptoms in patients with Cushing’s syndrome or autonomous cortisol secretion.
• 📰Recurrent Metatarsal Fractures in a Patient With Cushing Disease
  A 39-year-old premenopausal woman presented to the orthopedic outpatient clinic with recurrent metatarsal fractures and no history of trauma. A metabolic bone disease was suspected, and after further evaluation by endocrinology services, Cushing's Disease was diagnosed.
• ⭐️ Top Picks on the Message Boards updated May 16, 2022
  Top content from across the message boards, hand-picked by MaryO and the Cushing's community.
• 📰Osilodrostat Resolves Most Physical Signs of Cushing's Disease
  Not only was central obesity the most common physical manifestation associated with hypercortisolism among these Cushing's disease patients, but it was also more frequently rated as severe at baseline
• 📰 Intermittent Blurry Vision: An Unexpected Presentation of Cushing’s Syndrome Due to Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH)
  Our patient’s presentation was unusual as she presented at 40 years old, 10 years earlier than expected for PBMAH; and primarily with complaints of episodic blurry vision. Her symptoms also progressed rapidly as signs and symptoms largely presented over the course of 12 months, however responded well to surgical resection.
• 📰 The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas
  Corticotroph cells give rise to aggressive and rare pituitary neoplasms comprising ACTH-producing adenomas resulting in Cushing disease (CD), clinically silent ACTH adenomas (SCA), Crooke cell adenomas (CCA) and ACTH-producing carcinomas (CA).
• 📰 Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
  Literature regarding endogenous Cushing syndrome (CS) largely focuses on the challenges of diagnosis, subtyping, and treatment. The enigmatic phenomenon of glucocorticoid withdrawal syndrome (GWS), due to rapid reduction in cortisol exposure following treatment of CS, is less commonly discussed but also difficult to manage. We highlight the clinical approach […]
• 📰 Levoketoconazole improves cortisol control in endogenous Cushing’s syndrome
  Compared with placebo, levoketoconazole improved cortisol control and serum cholesterol levels for adults with endogenous Cushing’s syndrome
• 📰 Safety of Long-Term Growth Hormone Treatment Assessed
  A worldwide, observational study of adults and adolescents with growth hormone deficiency (GHD) found long-term GH replacement was safe. These findings were published in the Journal of Clinical Endocrinology & Metabolism. … The most common all-cause adverse events included arthralgia (4.6%), peripheral edema (3.9%), headache (3.6%), influenza (2.8%), dep […]
• 📰 Copeptin Levels Before and After Transsphenoidal Surgery for Cushing Disease: A Potential Early Marker of Remission
  A difference in peak postoperative plasma copeptin as an early marker to predict remission of CD was not consistently present, although the data point to the need for a larger sample size to further evaluate this. However, the utility of this test may be limited to those who develop neither DI nor SIADH postoperatively.
• 👍 Human Growth Hormone Study
  Research opportunity for Human Growth Hormone Deficiency caregivers of adolescent patients. This is a 75 min web-assisted phone interview, and the compensation is $125.
• 🖤 In Memory of Melinda Smith ~ May 9, 2014
  Sadly, we lost another Cushing’s patient on Friday, May 9, 2014. Melinda was a member of the Cushing’s Help message boards since Jun 24, 2007. She was only 25 and left behind a young son and many loving family members.
• 📰 Sharmyn, In The Media
  In the media: Sharmyn had pituitary Cushing's and is in remission. This is a compilation of some of her interviews and videos.
• ‼️ Message Board Downtime This Week
  Our community will experience a single, brief period of downtime this week. The exact timing is not known as this is a rolling update. There will be no data loss and most communities will see a downtime window of less than 10 minutes.
• 🖤 In Memory of Gregory J. Bart Jr. ~ May 7, 2016
  He died of a presumed heart attack. September 19, 2015 he said ''I was diagnosed hypertensive way back when I was 20. The condition remained for years, and became more acute with my cushings pit tumor. I still have high blood pressure, partially teated with three meds. I'll have to consult my doc and see if this may also be an issue.'
• 📰 The effect of endogenous Cushing's syndrome on all-cause and cause-specific mortality
  Despite improved outcomes in recent years, increased mortality from CS persists. The causes of death highlight the need to prevent and manage co-morbidities in addition to treating hypercortisolism.
• 📰 Osilodrostat Effective for Patients With Cushing Disease
  Osilodrostat is associated with rapid normalization of mean urinary free cortisol (mUFC) excretion in patients with Cushing disease and has a favorable safety profile, according to the results of a study published in the Journal of Clinical Endocrinology & Metabolism.